NCT05247684View on ClinicalTrials.gov

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 20, 2022

Primary Completion Date

August 20, 2023

Study Completion Date

January 20, 2025

Conditions
Resectable Non-small Cell Lung Cancer
Interventions
DRUG

AK112

IV infusion

DRUG

Carboplatin

IV infusion

DRUG

Cisplatin

IV infusion

DRUG

Paclitaxel

IV infusion

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT05247684 - AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC | Biotech Hunter | Biotech Hunter